Corbus Pharmaceuticals
CRBP
100 hedge funds and large institutions have $108M invested in Corbus Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 9 closing their positions.
16,967% more call options, than puts
Call options by funds: $512K | Put options by funds: $3K
211% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 9
23% more funds holding
Funds holding: 81 → 100 (+19)
3.64% more ownership
Funds ownership: 71.81% → 75.45% (+3.6%)
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
1% less capital invested
Capital invested by funds: $109M → $108M (-$1.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$14M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.4M |
| 3 |
O
OrbiMed
New York
|
+$5.25M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.81M |
| 5 |
AC
Armistice Capital
New York
|
+$4.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$1.97M |
| 2 |
Morgan Stanley
New York
|
-$1.63M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.61M |
| 4 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$1.49M |
| 5 |
Millennium Management
New York
|
-$1.23M |
CRBP Hedge Fund Activity: Q4 2025 in Review
100 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2025, worth a combined $108M — down 1.4% from $109M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CRBP positions and 9 closed out — a net gain of 19 holders — while 25 added to existing stakes and 23 trimmed.
The largest buyer was Aberdeen Group, adding an estimated $14M. The largest seller was Octagon Capital Advisors, cutting an estimated $1.97M.
- 100 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2025, up from 81 in Q3 2025.
- Funds reported $108M of Corbus Pharmaceuticals stock for Q4 2025, down 1.4% quarter-over-quarter.
- 28 funds opened new Corbus Pharmaceuticals positions in Q4 2025 and 9 closed out, a net change of +19 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2025 was Aberdeen Group, an estimated $14M added.
- The largest Corbus Pharmaceuticals seller in Q4 2025 was Octagon Capital Advisors, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2025.